Etiology of Ibrutinib Discontinuation and Outcomes in Chronic Lymphocytic Leukemia Patients

IMPORTANCE: The Bruton’s Tyrosine Kinase inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuation from this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. OBJECTI...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Maddocks, Kami J., Ruppert, Amy S., Lozanski, Gerard, Heerema, Nyla A., Zhao, Weiqiang, Abruzzo, Lynne, Lozanski, Arletta, Davis, Melanie, Gordon, Amber, Smith, Lisa L., Mantel, Rose, Jones, Jeffrey A., Flynn, Joseph M., Jaglowski, Samantha M., Andritsos, Leslie A., Awan, Farrukh, Blum, Kristie A., Grever, Michael R., Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4520535/
https://ncbi.nlm.nih.gov/pubmed/26182309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2014.218
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky